Loading...
Market
Impact of Novavax-Sanofi partnership on Novavax's market position by end of 2024
4
Resolution / Starting Odds
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Market analysis reports and company financial statements
Story
Novavax, Sanofi Ink $1.2B Deal; Novavax Stock Surges Over 140%
May 10, 2024, 05:10 PM
Novavax has entered into a significant licensing agreement with Sanofi, valued up to $1.2 billion, to commercialize its COVID-19 vaccine and develop a combined COVID-19 and flu vaccine. The deal includes an upfront payment of $500 million from Sanofi, which also takes a 4.9% equity stake in Novavax. This partnership aims to leverage both companies' capabilities to enhance vaccine availability and efficacy, particularly as COVID-19 vaccination rates are expected to stabilize post-pandemic. The agreement has led to a substantial increase in Novavax's stock, which surged over 140% following the announcement.
View original story
Similar markets
Top performer • 33%
Average performer • 34%
Below average performer • 33%
Novavax outperforms Sanofi • 50%
Sanofi outperforms Novavax • 50%
Approved in USA • 25%
Approved in EU • 25%
Approved in both USA and EU • 25%
Not approved in either • 25%
Significant Increase (>15%) • 33%
Moderate Increase (5-15%) • 33%
Little to No Change (<5%) • 33%
10-20% increase • 25%
21-50% increase • 25%
51-100% increase • 25%
more than 100% increase • 25%
Over 50 countries • 25%
30-50 countries • 25%
10-29 countries • 25%
Under 10 countries • 25%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Novavax/Sanofi leads • 33%
Pfizer/BioNTech leads • 33%
Moderna leads • 33%